Protagonist Therapeutics (PTGX) Total Non-Current Liabilities (2015 - 2021)

Protagonist Therapeutics (PTGX) reported Total Non-Current Liabilities of $43.4 million for Q3 2021, down 8.76% on a YoY basis from $47.6 million in Q3 2020, and down 7.01% sequentially from $46.7 million in Q2 2021.

Protagonist Therapeutics (PTGX) Total Non-Current Liabilities (2015 - 2021) Analysis & Trends

Protagonist Therapeutics (PTGX) has 3 years of Total Non-Current Liabilities data on file, last reported at $43.4 million in Q3 2021.

  • For the quarter ending Q3 2021, Total Non-Current Liabilities fell 8.76% year-over-year to $43.4 million; the trailing twelve-month figure through Sep 2021 stood at $43.4 million (down 8.76% YoY), and the FY2020 full-year result was $44.7 million, changed N/A from the prior year.
  • Total Non-Current Liabilities declined to $43.4 million in Q3 2021, from $46.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $57.4 million in Q2 2020 to a low of $38.6 million in Q1 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Protagonist Therapeutics 8.81 Bn 8.81 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2021 43.39 Mn
Jun 30, 2021 46.66 Mn
Mar 31, 2021 38.62 Mn
Dec 31, 2020 44.74 Mn
Sep 30, 2020 47.56 Mn
Jun 30, 2020 57.40 Mn
Dec 31, 2015 3.13 Mn